CG Oncology (CGON) Projected to Post Quarterly Earnings on Tuesday

CG Oncology (NASDAQ:CGON) is anticipated to announce its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.57) per share and revenue of $0.0730 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 12:30 PM ET.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 19.37%. On average, analysts expect CG Oncology to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CG Oncology Price Performance

Shares of NASDAQ CGON traded down $0.90 during mid-day trading on Tuesday, hitting $41.00. The company had a trading volume of 19,436 shares, compared to its average volume of 986,637. The company has a market capitalization of $3.13 billion, a PE ratio of -23.22 and a beta of 1.32. The business’s 50-day simple moving average is $37.55 and its 200 day simple moving average is $29.87. CG Oncology has a 1-year low of $14.80 and a 1-year high of $45.56.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on CGON shares. The Goldman Sachs Group raised CG Oncology to a “strong-buy” rating and set a $40.00 price objective on the stock in a report on Thursday, July 10th. Royal Bank Of Canada dropped their price objective on CG Oncology from $68.00 to $53.00 and set an “outperform” rating on the stock in a report on Wednesday, July 16th. JPMorgan Chase & Co. increased their target price on shares of CG Oncology from $41.00 to $47.00 and gave the stock an “overweight” rating in a research note on Friday, September 26th. Morgan Stanley increased their target price on shares of CG Oncology from $56.00 to $79.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 17th. Finally, Jones Trading started coverage on shares of CG Oncology in a research note on Monday, September 8th. They set a “buy” rating and a $50.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $58.70.

Insider Transactions at CG Oncology

In related news, Director Leonard E. Post sold 5,000 shares of CG Oncology stock in a transaction that occurred on Tuesday, September 30th. The stock was sold at an average price of $40.09, for a total transaction of $200,450.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brian Guan-Chyun Liu acquired 1,515,151 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The shares were bought at an average price of $33.00 per share, with a total value of $49,999,983.00. Following the completion of the transaction, the director directly owned 1,515,151 shares in the company, valued at approximately $49,999,983. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders sold 174,359 shares of company stock valued at $5,511,784.

Institutional Investors Weigh In On CG Oncology

Several hedge funds have recently made changes to their positions in the business. Invesco Ltd. grew its stake in shares of CG Oncology by 5.3% during the 2nd quarter. Invesco Ltd. now owns 29,231 shares of the company’s stock valued at $760,000 after buying an additional 1,477 shares during the period. Federated Hermes Inc. raised its stake in CG Oncology by 20.0% during the second quarter. Federated Hermes Inc. now owns 10,200 shares of the company’s stock worth $265,000 after acquiring an additional 1,700 shares during the period. New York State Common Retirement Fund raised its stake in CG Oncology by 27.2% during the second quarter. New York State Common Retirement Fund now owns 17,796 shares of the company’s stock worth $463,000 after acquiring an additional 3,800 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of CG Oncology by 159.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock worth $182,000 after buying an additional 4,288 shares during the period. Finally, PDT Partners LLC boosted its position in shares of CG Oncology by 6.5% during the second quarter. PDT Partners LLC now owns 72,143 shares of the company’s stock worth $1,876,000 after buying an additional 4,426 shares during the period. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.